Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Alzheimer's Disease

Free Subscription 21.11.2022 17 Alzheimers Dement 1 Ann Neurol 4 Curr Alzheimer Res 16 J Alzheimers Dis 1 J Am Geriatr Soc 1 J Neurol 1 J Neurol Neurosurg Psychiatry 1 J Neurosci 1 Nat Med 4 Nature 5 Neurology 1 Neuropsychology 2 Neurosci Lett 2 Neuroscience 2 PLoS One 1 Rev Neurol (Paris) 1 Science

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Alzheimers Dement

1. KARPOUZIAN-ROGERS T, Ho E, Novack M, Chinkers M, et al
   Baseline characterization of the ARMADA (Assessing Reliable Measurement in Alzheimer's Disease) study cohorts.
   Alzheimers Dement. 2022 Nov 17. doi: 10.1002/alz.12816.
   PubMed         Abstract available
   
   
2. GOLDHARDT O, Freiberger R, Dreyer T, Wilner L, et al
   Herpes simplex virus alters Alzheimer's disease biomarkers - A hypothesis paper.
   Alzheimers Dement. 2022 Nov 17. doi: 10.1002/alz.12834.
   PubMed         Abstract available
   
   
3. HUANG J, Stein TD, Wang Y, Ang TFA, et al
   Blood levels of MCP-1 modulate the genetic risks of Alzheimer's disease mediated by HLA-DRB1 and APOE for Alzheimer's disease.
   Alzheimers Dement. 2022 Nov 17. doi: 10.1002/alz.12851.
   PubMed         Abstract available
   
   
4. POLSINELLI AJ, Logan PE, Lane KA, Manchella MK, et al
   APOE epsilon4 carrier status and sex differentiate rates of cognitive decline in early- and late-onset Alzheimer's disease.
   Alzheimers Dement. 2022 Nov 17. doi: 10.1002/alz.12831.
   PubMed         Abstract available
   
   
5. PANG M, Zhu L, Gabelle A, Gafson AR, et al
   Toward the end of a controversy on the effect of reduction in brain amyloid levels on change in cognitive and functional decline in Alzheimer's disease-Reply to a letter.
   Alzheimers Dement. 2022 Nov 16. doi: 10.1002/alz.12864.
   PubMed        
   
   
6. REIMAN EM, Pruzin JJ, Rios-Romenets S, Brown C, et al
   A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial.
   Alzheimers Dement. 2022 Nov 14. doi: 10.1002/alz.12843.
   PubMed         Abstract available
   
   
7. MINDT MR, Okonkwo O, Weiner MW, Veitch DP, et al
   Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under-represented populations.
   Alzheimers Dement. 2022 Nov 13. doi: 10.1002/alz.12823.
   PubMed         Abstract available
   
   
8. CHEN XQ, Zuo X, Becker A, Head E, et al
   Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer's disease and the Dp16 mouse Down syndrome model: Impact of APP gene dose.
   Alzheimers Dement. 2022 Nov 12. doi: 10.1002/alz.12835.
   PubMed         Abstract available
   
   
9. HSHIEH TT, Gou RY, Jones RN, Leslie DL, et al
   One-year Medicare costs associated with delirium in older hospitalized patients with and without Alzheimer's disease dementia and related disorders.
   Alzheimers Dement. 2022 Nov 10. doi: 10.1002/alz.12826.
   PubMed         Abstract available
   
   
10. 
    Improving community health-care systems' early detection of cognitive decline and dementia.
    Alzheimers Dement. 2022;18:2375-2381.
    PubMed         Abstract available
    
    
11. TEMP AGM, Ly A, van Doorn J, Wagenmakers EJ, et al
    A Bayesian perspective on Biogen's aducanumab trial.
    Alzheimers Dement. 2022;18:2341-2351.
    PubMed         Abstract available
    
    
12. LECCA D, Jung YJ, Scerba MT, Hwang I, et al
    Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis.
    Alzheimers Dement. 2022;18:2327-2340.
    PubMed         Abstract available
    
    
13. HEGAZY SH, Thomassen JQ, Rasmussen IJ, Nordestgaard BG, et al
    C-reactive protein levels and risk of dementia-Observational and genetic studies of 111,242 individuals from the general population.
    Alzheimers Dement. 2022;18:2262-2271.
    PubMed         Abstract available
    
    
14. BHASIN H, Agrawal RK
    Triploid genetic algorithm for convolutional neural network-based diagnosis of mild cognitive impairment.
    Alzheimers Dement. 2022;18:2283-2291.
    PubMed         Abstract available
    
    
15. KULLER LH, Snitz BE, Hughes TM, Chang Y, et al
    Low untreated systolic blood pressure over 18 years is associated with survival free of dementia age 90.
    Alzheimers Dement. 2022;18:2176-2187.
    PubMed         Abstract available
    
    
16. PADOVANI A, Canale A, Schiavon L, Masciocchi S, et al
    Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis.
    Alzheimers Dement. 2022;18:2167-2175.
    PubMed         Abstract available
    
    
17. BELLEVILLE S, Cloutier S, Mellah S, Willis S, et al
    Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia.
    Alzheimers Dement. 2022;18:2140-2150.
    PubMed         Abstract available
    
    

    
    Ann Neurol

18. LAHNA D, Schwartz DL, Woltjer R, Black SE, et al
    Venous Collagenosis as Pathogenesis of White Matter Hyperintensity.
    Ann Neurol. 2022;92:992-1000.
    PubMed         Abstract available
    
    

    
    Curr Alzheimer Res

19. NI X, Mori H
    Complex Processes Underlying the Dynamic Changes of D-serine Levels in AD Brains.
    Curr Alzheimer Res. 2022;19:485-493.
    PubMed         Abstract available
    
    
20. GE X, Yao T, Zhang C, Wang Q, et al
    Human microRNA-4433 (hsa-miR-4443) Targets 18 Genes to be a Risk Factor of Neurodegenerative Diseases.
    Curr Alzheimer Res. 2022;19:511-522.
    PubMed         Abstract available
    
    
21. SCHURAD B, Koch C, Schug B, Morte A, et al
    Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon(R) Transdermal Patch (Daily)- A Randomized Clinical Trial.
    Curr Alzheimer Res. 2022;19:541-553.
    PubMed         Abstract available
    
    
22. ZHAO J, Wang J, Zhao D, Wang L, et al
    Association Between ABCA1 R219K Variant And Alzheimer's Disease: An Updated Meta-Analysis And Systematic Review.
    Curr Alzheimer Res. 2022 Nov 14. pii: CAR-EPUB-127559.
    PubMed         Abstract available
    
    

    
    J Alzheimers Dis

23. JOSHI MS, Galvin JE
    Cognitive Resilience in Brain Health and Dementia Research.
    J Alzheimers Dis. 2022;90:461-473.
    PubMed         Abstract available
    
    
24. SONG Y, Quan M, Li T, Jia J, et al
    Serum Homocysteine, Vitamin B12, Folate, and Their Association with Mild Cognitive Impairment and Subtypes of Dementia.
    J Alzheimers Dis. 2022;90:681-691.
    PubMed         Abstract available
    
    
25. VIPIN A, Koh CL, Wong BYX, Zailan FZ, et al
    Amyloid-Tau-Neurodegeneration Profiles and Longitudinal Cognition in Sporadic Young-Onset Dementia.
    J Alzheimers Dis. 2022;90:543-551.
    PubMed         Abstract available
    
    
26. WANG Z, Wang J, Liu N, Liu C, et al
    Learning Cognitive-Test-Based Interpretable Rules for Prediction and Early Diagnosis of Dementia Using Neural Networks.
    J Alzheimers Dis. 2022;90:609-624.
    PubMed         Abstract available
    
    
27. ROVCANIN DRAGOVIC I, Popovic N, Zdralevic M, Radulovic L, et al
    Inflammation-Related microRNAs-146a and -155 Are Upregulated in Mild Cognitive Impairment Subjects Among Older Age Population in Montenegro.
    J Alzheimers Dis. 2022;90:625-638.
    PubMed         Abstract available
    
    
28. O'BRYANT SE, Petersen M, Hall J, Johnson LA, et al
    Characterization of Mild Cognitive Impairment and Dementia among Community-Dwelling Mexican Americans and Non-Hispanic Whites.
    J Alzheimers Dis. 2022;90:905-915.
    PubMed         Abstract available
    
    
29. YANG YH, Hsieh SW, Chang HW, Sung JL, et al
    Gamma Frequency Inhibits the Secretion and Aggregation of Amyloid-beta and Decreases the Phosphorylation of mTOR and Tau Proteins in vitro.
    J Alzheimers Dis. 2022;90:917-928.
    PubMed         Abstract available
    
    
30. AERQIN Q, Jia SS, Shen XN, Li Q, et al
    Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study.
    J Alzheimers Dis. 2022;90:761-773.
    PubMed         Abstract available
    
    
31. BLIVET G, Relano-Gines A, Wachtel M, Touchon J, et al
    A Randomized, Double-Blind, and Sham-Controlled Trial of an Innovative Brain-Gut Photobiomodulation Therapy: Safety and Patient Compliance.
    J Alzheimers Dis. 2022;90:811-822.
    PubMed         Abstract available
    
    
32. RABI R, Chow R, Paracha S, Hasher L, et al
    Time of Day Effects on Inhibitory Functioning: Cognitive and Neural Evidence of Sundowning in Amnestic Mild Cognitive Impairment.
    J Alzheimers Dis. 2022;90:869-890.
    PubMed         Abstract available
    
    
33. SHEPHERD-BANIGAN ME, Ford CB, Smith VA, Belanger E, et al
    Amyloid-beta PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time.
    J Alzheimers Dis. 2022;90:775-782.
    PubMed         Abstract available
    
    
34. VALLES-SALGADO M, Cabrera-Martin MN, Curiel-Cid RE, Delgado-Alvarez A, et al
    Neuropsychological, Metabolic, and Connectivity Underpinnings of Semantic Interference Deficits Using the LASSI-L.
    J Alzheimers Dis. 2022;90:823-840.
    PubMed         Abstract available
    
    
35. JOHNSON AL, Seep E, Norton DL, Mundt MP, et al
    Wisconsin Healthcare Utilization Cost Among American Indians/Alaska Natives with and without Alzheimer's Disease and Related Dementias.
    J Alzheimers Dis. 2022 Nov 8. pii: JAD220393. doi: 10.3233/JAD-220393.
    PubMed         Abstract available
    
    
36. LIU Z, Zhang H, Liu S, Hou Y, et al
    The Dual Role of Astrocyte-Derived Exosomes and Their Contents in the Process of Alzheimer's Disease.
    J Alzheimers Dis. 2022 Nov 11. pii: JAD220698. doi: 10.3233/JAD-220698.
    PubMed         Abstract available
    
    
37. DOVER M, Moseley T, Biskaduros A, Paulchakrabarti M, et al
    Polyunsaturated Fatty Acids Mend Macrophage Transcriptome, Glycome, and Phenotype in the Patients with Neurodegenerative Diseases, Including Alzheimer's Disease.
    J Alzheimers Dis. 2022 Nov 8. pii: JAD220764. doi: 10.3233/JAD-220764.
    PubMed         Abstract available
    
    
38. CHEN L, Xue J, Zhao Q, Liang X, et al
    A Pilot Study of Near-Infrared Light Treatment for Alzheimer's Disease.
    J Alzheimers Dis. 2022 Nov 11. pii: JAD220866. doi: 10.3233/JAD-220866.
    PubMed         Abstract available
    
    

    
    J Am Geriatr Soc

39. LIU R, Ren Y, Hou T, Liang X, et al
    Associations of sleep timing and time in bed with dementia and cognitive decline among Chinese older adults: A cohort study.
    J Am Geriatr Soc. 2022;70:3138-3151.
    PubMed         Abstract available
    
    

    
    J Neurol

40. LI Y, Chen Z, Wang Q, Lv X, et al
    Identification of hub proteins in cerebrospinal fluid as potential biomarkers of Alzheimer's disease by integrated bioinformatics.
    J Neurol. 2022 Nov 18. pii: 10.1007/s00415-022-11476.
    PubMed         Abstract available
    
    

    
    J Neurol Neurosurg Psychiatry

41. AYTON S, Janelidze S, Kalinowski P, Palmqvist S, et al
    CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers.
    J Neurol Neurosurg Psychiatry. 2022 Nov 10. pii: jnnp-2022-330052.
    PubMed         Abstract available
    
    

    
    J Neurosci

42. NASSIF C, Kawles A, Ayala I, Minogue G, et al
    Integrity of Neuronal Size in the Entorhinal Cortex Is a Biological Substrate of Exceptional Cognitive Aging.
    J Neurosci. 2022;42:8587-8594.
    PubMed         Abstract available
    
    

    
    Nat Med

43. MOUTINHO S
    The long road to a cure for Alzheimer's disease is paved with failures.
    Nat Med. 2022;28:2228-2231.
    PubMed        
    
    

    
    Nature

44. WAGNER J, Degenhardt K, Veit M, Louros N, et al
    Medin co-aggregates with vascular amyloid-beta in Alzheimer's disease.
    Nature. 2022 Nov 16. pii: 10.1038/s41586-022-05440.
    PubMed         Abstract available
    
    
45. DOLGIN E
    This is how an Alzheimer's gene ravages the brain.
    Nature. 2022 Nov 16. pii: 10.1038/d41586-022-03724.
    PubMed        
    
    
46. PETRIC HOWE N, Thompson B
    How a key Alzheimer's gene wreaks havoc in the brain.
    Nature. 2022 Nov 16. pii: 10.1038/d41586-022-03746.
    PubMed        
    
    
47. CARLSTROM K, Castelo-Branco G
    Alzheimer's risk variant APOE4 linked to myelin-assembly malfunction.
    Nature. 2022 Nov 16. pii: 10.1038/d41586-022-03371.
    PubMed        
    
    

    
    Neurology

48. HUANG J, Su B, Karhunen V, Gill D, et al
    Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization.
    Neurology. 2022 Nov 16. pii: WNL.0000000000201489.
    PubMed         Abstract available
    
    
49. YU L, Hsieh YC, Pearse RV, Wang Y, et al
    Association of AK4 Protein From Stem Cell-Derived Neurons With Cognitive Reserve: An Autopsy Study.
    Neurology. 2022;99:e2264-e2274.
    PubMed         Abstract available
    
    
50. QIU WQ, Tao Q, Akhter-Khan SC
    Author Response: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:919.
    PubMed        
    
    
51. GANESH A, Galetta S
    Editors' Note: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:918.
    PubMed        
    
    
52. ROYALL DR
    Reader Response: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:918-919.
    PubMed        
    
    

    
    Neuropsychology

53. YLIRANTA A, Nuorva J, Karjalainen VL, Ahmasalo R, et al
    The dementia apraxia test can detect early-onset Alzheimer's disease.
    Neuropsychology. 2022 Nov 14. pii: 2023-17660-001. doi: 10.1037/neu0000873.
    PubMed         Abstract available
    
    

    
    Neurosci Lett

54. FARHANGIAN M, Azarafrouz F, Chavoshinezhad S, Dargahi L, et al
    Intranasal interferon-beta alleviates anxiety and depressive-like behaviors by modulating microglia polarization in an Alzheimer's disease model.
    Neurosci Lett. 2022 Nov 14:136968. doi: 10.1016/j.neulet.2022.136968.
    PubMed         Abstract available
    
    
55. FOLORUNSO OO, Harvey TL, Brown SE, Chelini G, et al
    The D-serine biosynthetic enzyme serine racemase is expressed by reactive astrocytes in the amygdala of human and a mouse model of Alzheimer's disease.
    Neurosci Lett. 2022;792:136958.
    PubMed         Abstract available
    
    

    
    Neuroscience

56. ANAND S, Azam Ansari M, Kumaraswamy Sukrutha S, Alomary MN, et al
    Resolvins lipid mediators: Potential therapeutic targets in Alzheimer and Parkinson disease.
    Neuroscience. 2022 Nov 10. pii: S0306-4522(22)00546.
    PubMed         Abstract available
    
    
57. YANG L, Nao J
    Focus on Alzheimer's disease: the role of fibroblast growth factor 21 and autophagy.
    Neuroscience. 2022 Nov 10. pii: S0306-4522(22)00548.
    PubMed         Abstract available
    
    

    
    PLoS One

58. BARTELS SL, Shaaban CE, Brum WS, Welikovitch LA, et al
    Impact of the COVID-19 pandemic on early career dementia researchers: A global online survey.
    PLoS One. 2022;17:e0277470.
    PubMed         Abstract available
    
    
59. KARAMAN BK, Mormino EC, Sabuncu MR
    Machine learning based multi-modal prediction of future decline toward Alzheimer's disease: An empirical study.
    PLoS One. 2022;17:e0277322.
    PubMed         Abstract available
    
    

    
    Rev Neurol (Paris)

60. DELABY C, Hirtz C, Lehmann S
    Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges.
    Rev Neurol (Paris). 2022 Nov 9. pii: S0035-3787(22)00792.
    PubMed         Abstract available
    
    

    
    Science

61. ENDO F, Kasai A, Soto JS, Yu X, et al
    Molecular basis of astrocyte diversity and morphology across the CNS in health and disease.
    Science. 2022;378:eadc9020.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: